Entering text into the input field will update the search result below
Create free account
Search for Symbols, analysts, keywords
Log in
Analysis
All Analysis
Basic Materials
Biotech
Bonds
Closed End Funds
Commodities
Communication Services
Consumer
Consumer Staples
Cryptocurrency
Dividend Ideas
Dividend Quick Picks
Dividend Strategy
Dividends
Economy
Editors' Picks
Energy
ETF Analysis
ETFs and Funds
Financial Advisor
Financials
Fixed Income
Forex
Gold & Precious Metals
Growth
Healthcare
Industrial
Investing Strategy
IPOs
Long Ideas
Market Outlook
Micro-Caps
Mutual Funds
Portfolio Strategy
Quick Picks & Lists
Real Estate
REITs
Retirement
Small-Caps
Stock Ideas
Tech
Utilities
Value
Micro-Cap Stocks
Cidara Therapeutics: Now Well-Funded To Advance Its Cloudbreak Platform
Sagimet Biosciences' Denifanstat Imminent Phase 3: A Promising Investment Opportunity
Adaptimmune: Huge Opportunity Amid Their Setback With Genentech
CytomX Therapeutics: I'm Bullish; There's More Than One Masked Immunotherapy Company In Town
Vistagen Therapeutics: A Pipeline With Potential In Anxiety And Depression
Inovio Pharmaceuticals: Neutral On INO-3107 Amidst Stock Dilution And High Valuation
Abeona Therapeutics Tanks On CRL From The FDA, But All Hope Is Not Lost
Spero Therapeutics Delivers On Game Plan To Create Shareholder Value
Inovio Pharmaceuticals: The Dilution Continues
InterCure: Bargain Israel Cannabis Play
Elevation Oncology: Continuing To Seek Footing As It Climbs (Rating Upgrade)
INmune Bio: An Opportunity In The Freefall (Rating Upgrade)
Ocugen: Two Gene Therapy Data Readouts In 2024 To Drive Value
Barnes & Noble Education: Shares Crater After Proposed Recapitalization - Hold
Sellas Life Sciences Group: A Lottery Ticket With An Estimated 6x Payout
Caribou Biosciences: 2 Clinical Data Updates In 2024 Could Bring Value
Pedevco Corp.: Speculative, Unhedged, Oily Micro Cap E&P With Upside Potential
Tempest Therapeutics: Multiple 2024 Catalysts Make This A Must Watch
PetroChina Remains Reasonably Valued, Despite Its Vast Outperformance
Heron Therapeutics: Zynrelef Potentially Eases Shareholder Pain
Amarin Corporation: Small Signs Of Recovery May Not Be Enough
My Best Current Micro-Cap Idea: BuzzFeed, Inc.
Buy Solid Biosciences: Unpacking Its Main Value Driver
Mereo BioPharma's Pipeline Promise Vs. Valuation And Market Realities
Lexeo: Targeted Alzheimer's Disease Treatment Approach Might Pay Off
FLYHT Aerospace: 2 Incoming Monopolies Practically Free
Gritstone bio: GRANITE Cancer Vaccine Data Overshadowed By Offering
Vanda Pharmaceuticals: Fanapt Bipolar Win Doesn't Change Much
Buy Vafseo's Approval: A New Chapter For Akebia Therapeutics In Anemia Management
Werewolf Therapeutics: In The Hunt For Success In The Cytokine Space
Achieve Life Sciences: An Excellent Drug Addressing A Large Market Could Drive 5x Returns
Canadian NET REIT Offers A 7% Yield With A ~60% Payout Ratio
2seventy Bio: Maximizing ABECMA's Potential To Fuel A Turnaround
Silver Spike Investment Q4: This Cannabis BDC Looks Poised For Growth
Scynexis: Update Following Restructuring Of GSK Deal
Velo3D: No Room For Error
Akebia's Vafseo Faces Grim Market Outlook (Rating Downgrade)
CervoMed: H2 2024 Data For DLB Program A Major Inflection Point
Evaxion: An Intriguing AI Vaccine Company With Big Pharma Collaboration
Omega Therapeutics And Novo Nordisk Collaboration: A Cautious 'Buy'
1
2
Next